Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
What is the ticker symbol for Kodiak Sciences Inc? What does KOD stand for in stocks?
KOD is the stock ticker symbol of Kodiak Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Kodiak Sciences Inc (KOD)?
As of Fri Dec 27 2024, market cap of Kodiak Sciences Inc is 526.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of KOD stock?
You can check KOD's fair value in chart for subscribers.
Is Kodiak Sciences Inc a good stock to buy?
The fair value guage provides a quick view whether KOD is over valued or under valued. Whether Kodiak Sciences Inc is cheap or expensive depends on the assumptions which impact Kodiak Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KOD.